Recent Quotes (30 days)

You have no recent quotes
chg | %

Sunshine Biopharma, Inc.  

(Public, OTCMKTS:SBFM)   Watch this stock  
Find more results for OTC:SBFM
0.0399
0.0000 (0.00%)
After Hours: 0.0344 -0.0055 (-13.78%)
Nov 21, 4:03PM EST  
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.03 - 0.04
52 week 0.03 - 0.27
Open 0.04
Vol / Avg. 265,782.00/123,721.00
Mkt cap 2.75M
P/E     -
Div/yield     -
EPS -0.04
Shares 68.91M
Beta 22.29
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -1004.31% -3001.24%
Return on average equity - -7944.77%
Employees 3 -
CDP Score - -

Address

3rd Floor, 469 Jean-Talon West
MONTREAL, QC H3N 1R4
Canada
+1-514-7649698 (Phone)
+1-514-7649699 (Fax)

Website links

Description

Sunshine Biopharma, Inc. is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company�s lead compound, Adva-27a is a multi-purpose anti-tumor. Its drug candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. As of December 31, 2011, the Company planned to conduct its Phase I clinical trials for Adva-27a. In July 2014, the Company formed Sunshine Biopharma Canada Inc.

Officers and directors

Steve N. Slilaty Chairman of the Board, President, Chief Executive Officer
Age: 60
Camille Sebaaly Chief Financial Officer, Secretary, Director
Age: 53
Michele Di Turi Chief Operating Officer, Director
Age: 35